In fact, the WHO expert group (1996) defined thrombophilia as a tendency to develop VTE that may be genetically determined, acquired or both.5 Genetic factors include activated protein C resistance (APC-R) associated with Factor V Leiden mutation (FVL), Prothrombin G20210A mutation associated with high levels of prothrombin, genetic deficiencies of proteins C, S and antithrombin, and others. The gene discussed is F5; the disease is thrombophilia.